Natalie Holles, Third Harmonic CEO

Au­dentes’ for­mer CEO launch­es new biotech, with $155M for hives and in­flam­ma­tion

For­mer Au­dentes CEO Na­tal­ie Holles is ready to de­but her next project, and it’s one that’s mu­sic to her ears.

Third Har­mon­ic Bio launched Wednes­day morn­ing with a $105 mil­lion Se­ries B and a plan to change the game in chron­ic ur­ticaria, a con­di­tion with sev­er­al caus­es that caus­es se­vere and de­bil­i­tat­ing hives. Holles, who joined last Au­gust, said Third Har­mon­ic has a lead pro­gram al­ready in the clin­ic and ex­pects to launch a Phase Ib study lat­er this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.